litlas
Log inCreate account

Kongming Wu

Active 1999–2026

251
Papers
32,685
Citations
100
h-index
239
i10-index

Citations

Citations per year for Kongming Wu1976: 1 citations1977: 1 citations1996: 2 citations2000: 1 citations2001: 2 citations2002: 7 citations2003: 4 citations2004: 38 citations2005: 39 citations2006: 51 citations2007: 40 citations2008: 58 citations2009: 62 citations2010: 96 citations2011: 90 citations2012: 94 citations2013: 119 citations2014: 84 citations2015: 107 citations2016: 123 citations2017: 117 citations2018: 168 citations2019: 677 citations2020: 1,011 citations2021: 1,473 citations2022: 1,490 citations2023: 1,513 citations2024: 2,645 citations2025: 1,502 citations2026: 67 citations1978–1995: no citations, so these years are not shown1997–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 4,624 citing papers, 35.3% of this breakdownUnited States: 2,199 citing papers, 16.8% of this breakdownUnited Kingdom: 428 citing papers, 3.3% of this breakdownIndia: 415 citing papers, 3.2% of this breakdownGermany: 405 citing papers, 3.1% of this breakdownItaly: 405 citing papers, 3.1% of this breakdownSouth Korea: 282 citing papers, 2.2% of this breakdownFrance: 277 citing papers, 2.1% of this breakdownIran: 259 citing papers, 2% of this breakdownAustralia: 254 citing papers, 1.9% of this breakdownJapan: 212 citing papers, 1.6% of this breakdownCanada: 202 citing papers, 1.5% of this breakdown
0%35.3%Other 23.9%

Institutions

Fields

  • Medicine40.4%
  • Biochemistry, Genetics and Molecular Biology36.3%
  • Immunology and Microbiology9.8%
  • Agricultural and Biological Sciences4.7%
  • Engineering3.2%
  • Neuroscience1.9%
  • Other3.7%

Topics

  • Cancer Immunotherapy and Biomarkers6.3%
  • Insect Resistance and Genetics3.9%
  • Immunotherapy and Immune Responses3%
  • CAR-T cell therapy research3%
  • Immune cells in cancer2.8%
  • Cancer Cells and Metastasis2.3%
  • Other78.7%

Coauthors

All papers

Open in search
  1. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

    Authors: Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu - Molecular Cancer 2022 cited by 1,452

  2. Notch signaling pathway: architecture, disease, and therapeutics

    Authors: Binghan Zhou, Wanling Lin, Yaling Long, Yunkai Yang, Huan Zhang, Kongming Wu, Qian Chu - Signal Transduction and Targeted Therapy 2022 cited by 1,052

  3. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

    Authors: Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo - Molecular Cancer 2019 cited by 1,172

  4. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

    Authors: Yuze Wu, Ming Yi, Mengke Niu, Qi Mei, Kongming Wu - Molecular Cancer 2022 cited by 468

  5. Regulation of PD-L1 expression in the tumor microenvironment

    Authors: Ming Yi, Mengke Niu, Linping Xu, Suxia Luo, Kongming Wu - Journal of Hematology & Oncology 2021 cited by 672

  6. Recent advances in targeted strategies for triple-negative breast cancer

    Authors: Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu - Journal of Hematology & Oncology 2023 cited by 295

  7. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

    Authors: Ming Yi, Dechao Jiao, Shuang Qin, Qian Chu, Kongming Wu, Anping Li - Molecular Cancer 2019 cited by 611

  8. Targeting cytokine and chemokine signaling pathways for cancer therapy

    Authors: Ming Yi, Tianye Li, Mengke Niu, Haoxiang Zhang, Yuze Wu, Kongming Wu, Zhijun Dai - Signal Transduction and Targeted Therapy 2024 cited by 382

  9. Tumor organoids: applications in cancer modeling and potentials in precision medicine

    Authors: Hanxiao Xu, Dechao Jiao, Aiguo Liu, Kongming Wu - Journal of Hematology & Oncology 2022 cited by 260

  10. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

    Authors: Anping Li, Ming Yi, Shuang Qin, Yongping Song, Qian Chu, Kongming Wu - Journal of Hematology & Oncology 2019 cited by 436

  11. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

    Authors: Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu - Molecular Cancer 2018 cited by 793

  12. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

    Authors: Yuheng Yan, Lan Huang, Yiming Liu, Ming Yi, Qian Chu, Dechao Jiao, Kongming Wu - Journal of Hematology & Oncology 2022 cited by 205

  13. Targeting lysosomes in human disease: from basic research to clinical applications

    Authors: Mengdie Cao, Xiangyuan Luo, Kongming Wu, Xingxing He - Signal Transduction and Targeted Therapy 2021 cited by 213

  14. Exploiting innate immunity for cancer immunotherapy

    Authors: Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai, Kongming Wu - Molecular Cancer 2023 cited by 216

  15. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

    Authors: Ming Yi, Mengke Niu, Yuze Wu, Hong Ge, Dechao Jiao, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu, Kongming Wu - Journal of Hematology & Oncology 2022 cited by 178

  16. CD44 as a tumor biomarker and therapeutic target

    Authors: Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu, Aiguo Liu - Experimental Hematology and Oncology 2020 cited by 408

  17. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer

    Authors: Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu - Journal for ImmunoTherapy of Cancer 2022 cited by 161

  18. The CXCL8-CXCR1/2 pathways in cancer

    Authors: Qian Liu, Anping Li, Yijun Tian, Jennifer D. Wu, Yu Liu, Tengfei Li, Yuan Chen, Xinwei Han, Kongming Wu - Cytokine & Growth Factor Reviews 2016 cited by 669

  19. Invasiveness, biology, ecology, and management of the fall armyworm, Spodoptera frugiperda

    Authors: Marc Kenis, Giovanni Benelli, Antonio Biondi, Paul‐André Calatayud, Roger Day, Nicolas Desneux, Rhett D. Harrison, Darren J. Kriticos, Ivan Rwomushana, J. van den Berg, François Verheggen, Yongjun Zhang, Lakpo Koku Agboyi, Régis Besmer Ahissou, Malick N. Ba, Kongming Wu - Entomologia Generalis 2022 cited by 366

  20. Organoid technology and applications in cancer research

    Authors: Hanxiao Xu, Xiaodong Lyu, Ming Yi, Weiheng Zhao, Yongping Song, Kongming Wu - Journal of Hematology & Oncology 2018 cited by 356

  21. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

    Authors: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou, Kongming Wu - Journal of Hematology & Oncology 2021 cited by 253

  22. EGFR-TKIs resistance via EGFR-independent signaling pathways

    Authors: Qian Liu, Shengnan Yu, Weiheng Zhao, Shuang Qin, Qian Chu, Kongming Wu - Molecular Cancer 2018 cited by 391

  23. Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis

    Authors: Yu Jin, Yalin Kang, Minghuan Wang, Bili Wu, Beibei Su, Han Yin, Yang Tang, Qianxia Li, Wenjie Wei, Qi Mei, G. Hu, Veronika Lukacs‐Kornek, Jian Li, Kongming Wu, Xianglin Yuan, Wei Wang - Signal Transduction and Targeted Therapy 2022 cited by 169

  24. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

    Authors: Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu, Kongming Wu - Journal of Hematology & Oncology 2021 cited by 178